EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gut Microbiome Strategies for Enhancing ICI Delivery Across the BBB in Glioblastoma

Sama Barati, Sahar Ghoflchi, Ali Nakhaei iD, Mahla Palizkaran Yazdi, Pejman Hosseinzadeh, Hossein Hosseini, Mohammad Jalili-Nik iD

BioFactors · 2026

DOI: 10.1002/biof.70077 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioFactors, 2026. Verfasst von Sama Barati und 6 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Glioblastoma, Blood-Brain Barrier, Gastrointestinal Microbiome, Immune Checkpoint Inhibitors. Die Arbeit nennt 256 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GB) is highly malignant with a median survival of 14 months despite conventional treatments like surgery, radiotherapy, and temozolomide. Resistance to these therapies necessitates innovative approaches, such as immune checkpoint inhibitors (ICIs) targeting cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), programmed cell death protein 1 (PD‐1), and programmed death ligand 1 (PD‐L1) to enhance T‐cell‐mediated tumor destruction. However, clinical trials have shown limited ICI efficacy in GB due to its immunosuppressive microenvironment and the blood–brain tumor barrier (BBTB), which impairs drug delivery. Emerging evidence highlights the gut microbiota as a pivotal modulator of ICI response, enhancing CD8 + and CD4 + T‐cell function, antigen presentation, and immune modulation via the gut‐brain axis in cancers. In addition, studies showed that gut‐derived metabolites, including short‐chain fatty acids, modulate immune responses and support blood–brain barrier integrity by regulating inflammatory signaling and tight junction proteins. Future GB research should prioritize clinical trials, mechanistic studies, and interventional strategies like fecal microbiota transplantation and probiotics to enhance ICI efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBlood-Brain BarrierGastrointestinal MicrobiomeImmune Checkpoint InhibitorsBrain NeoplasmsHumansAnimalsTumor MicroenvironmentFecal Microbiota TransplantationCTLA-4 AntigenProgrammed Cell Death 1 ReceptorB7-H1 Antigen

Stichwörter der Autor:innen

blood–brain barrierglioblastomagut microbiomeimmune cellimmune checkpoint inhibitors

Substanzen

Immune Checkpoint InhibitorsCTLA-4 AntigenProgrammed Cell Death 1 ReceptorB7-H1 AntigenCTLA4 protein, humanPDCD1 protein, humanCD274 protein, human

Autor:innen und Institutionen

  • Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Student Research Committee, MMS.C, Islamic Azad University, Mashhad, Iran.
  • Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID-Profile: Ali Nakhaei, Mohammad Jalili-Nik

Zitieren

APA

Barati, S., Ghoflchi, S., Nakhaei, A., Yazdi, M. P., Hosseinzadeh, P., Hosseini, H., & Jalili-Nik, M. (2026). Gut Microbiome Strategies for Enhancing ICI Delivery Across the BBB in Glioblastoma. BioFactors. https://doi.org/10.1002/biof.70077

Vancouver

Barati S, Ghoflchi S, Nakhaei A, Yazdi MP, Hosseinzadeh P, Hosseini H, et al. Gut Microbiome Strategies for Enhancing ICI Delivery Across the BBB in Glioblastoma. BioFactors. 2026. doi:10.1002/biof.70077

BibTeX
@article{Barati2026,
  author = {Barati, Sama and Ghoflchi, Sahar and Nakhaei, Ali and Yazdi, Mahla Palizkaran and Hosseinzadeh, Pejman and Hosseini, Hossein and Jalili-Nik, Mohammad},
  title = {Gut Microbiome Strategies for Enhancing ICI Delivery Across the BBB in Glioblastoma},
  journal = {BioFactors},
  year = {2026},
  doi = {10.1002/biof.70077}
}
Kostenlos starten →